Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Net Cash Flow (2021 - 2025)

Historic Net Cash Flow for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $39.1 million.

  • Krystal Biotech's Net Cash Flow rose 4010.9% to $39.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year increase of 241152.26%. This contributed to the annual value of -$13.0 million for FY2024, which is 10661.55% down from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Net Cash Flow is $39.1 million, which was up 4010.9% from $44.0 million recorded in Q2 2025.
  • Krystal Biotech's 5-year Net Cash Flow high stood at $135.1 million for Q2 2023, and its period low was -$72.6 million during Q2 2021.
  • For the 5-year period, Krystal Biotech's Net Cash Flow averaged around $6.5 million, with its median value being -$14.8 million (2023).
  • Within the past 5 years, the most significant YoY rise in Krystal Biotech's Net Cash Flow was 44153.54% (2025), while the steepest drop was 748615.07% (2025).
  • Over the past 5 years, Krystal Biotech's Net Cash Flow (Quarter) stood at $54.6 million in 2021, then tumbled by 144.79% to -$24.5 million in 2022, then soared by 39.62% to -$14.8 million in 2023, then tumbled by 92.97% to -$28.5 million in 2024, then surged by 237.1% to $39.1 million in 2025.
  • Its Net Cash Flow was $39.1 million in Q3 2025, compared to $44.0 million in Q2 2025 and -$36.3 million in Q1 2025.